UBS Group AG (UBSG34)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 62.76 |
|---|---|
| 52-week range | 48.17 – 72.10 |
| Return, 1 month / 3 months | −2.3% / −6.2% |
| Return, 1 year / 3 years | +32.1% / +183.5% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 53 |
| Volatility (1 year) | 30.4% |
| Worst drawdown (1 year) | -26.1% |
| Average daily value traded | 0.02M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
UBS Group AG is a Swiss bank based in Zurich that provides wealth management, investment banking and asset management services. It advises private clients, family offices, institutional investors and corporations, helping them manage money, raise capital and trade securities. Its investment bank handles advisory work on mergers and acquisitions, plus trading in currencies, bonds and equities. The asset management arm runs funds and portfolios for institutions, while the wealth business serves wealthy individuals across many countries.
UBS Group AG is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code UBSG34, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
UBS Group AG (UBSG34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 62.76 on 27 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 422 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 32.1% and over the last three months it fell 6.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 64 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 6.1% | ||
| From 52-week high | -13.0% | ||
| Momentum | 60 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -6.2% | ||
| 6-month return | 19.6% | ||
| 12-month return, skipping the last month | 35.3% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.1% | ||
| Liquidity | 43 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.02M BRL | ||
| Zero-volume days | 5.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +5.2% |
|---|---|
| 1 month | −2.3% |
| 3 months | −6.2% |
| 6 months | +19.6% |
| 1 year | +32.1% |
| 3 years | +183.5% |
| 5 years | +333.8% |
Signals
| 50-day / 200-day average | 64.93 / 59.14 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.34 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 17 Apr 2026 | CHF 17.5656 |
| 14 Apr 2025 | CHF 16.4994 |
| 29 Apr 2024 | CHF 11.3218 |
| 11 Apr 2023 | CHF 8.6669 |
| 12 Apr 2022 | CHF 9.1908 |
| 11 Apr 2022 | CHF 7.4525 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.